Filtered By:
Drug: Aspirin
Procedure: Coronary Angioplasty
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 338 results found since Jan 2013.
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study
CONCLUSIONS: Dual antithrombotic therapy is associated with a substantially lower risk of clinically relevant bleeding without a statistically significant penalty in ischaemic events.PMID:35370126 | DOI:10.4244/EIJ-D-21-00703
Source: EuroIntervention - April 4, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Willem Lambertus Bor Anne Johanna Wilhelmina de Veer Renske H Olie Sem A O F Rikken Dean R P P Chan Pin Yin Jean Paul R Herrman Mathias Vrolix Martijn Meuwissen Tom Vandendriessche Carlos van Mieghem Michael Magro Naoual Bennaghmouch Rick Hermanides Tom A Source Type: research
Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial
CONCLUSIONS: Patients free from events at the end of the first year post-PCI and who adhered to their prescribed regimen had a reduced risk of ischaemic events compared to aspirin monotherapy in the second year post-PCI.CLINICALTRIALS: gov: NCT01813435.PMID:35260381 | DOI:10.4244/EIJ-D-21-00870
Source: EuroIntervention - March 9, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Masafumi Ono Hironori Hara Hideyuki Kawashima Chao Gao Rutao Wang Joanna J Wykrzykowska Jan J Piek Scot Garg Christian Hamm Philippe Gabriel Steg Marco Valgimigli Stephan Windecker Pascal Vranckx Yoshinobu Onuma Patrick W Serruys Source Type: research
EP News: Allied Professionals
In this non-prespecified, post hoc analysis of the AUGUSTUS (The Open-Label, 2 x 2 Factorial, Randomized, Controlled Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome and/or Percutaneous Coronary Intervention) trial (Harskamp et al. J Am Coll Cardiol. 2022;79:417-27. PMID-35115097), the authors sought to evaluate whether the risk of bleeding or stroke as assessed by baseline HAS-BLED and CHA2DS2-VASc scores affected the results of the trial.
Source: Heart Rhythm - March 9, 2022 Category: Cardiology Authors: Erica S. Zado Source Type: research
The WOEST 2 registry : A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention
CONCLUSIONS: Patients on combined oral anticoagulation and antiplatelet therapy undergoing PCI are elderly and have both a high bleeding and ischaemic risk. Over time, a NOAC plus clopidogrel became the preferred treatment. The rate of thrombotic and bleeding events was not significantly different between patients on triple or dual therapy or between those on VKAs versus NOACs.PMID:35230636 | DOI:10.1007/s12471-022-01664-0
Source: Netherlands Heart Journal - March 1, 2022 Category: Cardiology Authors: A J W M de Veer N Bennaghmouch W L Bor J P R Herrman M Vrolix M Meuwissen T Vandendriessche T Adriaenssens B de Bruyne M Magro W J M Dewilde J M Ten Berg Source Type: research
Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
CONCLUSION: In Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.PMID:34904209 | DOI:10.1007/s12325-021-01907-3
Source: Adv Data - December 14, 2021 Category: Epidemiology Authors: Dandan Li Yang Sun Xiaoran Ye Lanting Li Yundai Chen Daowen Wang Source Type: research
Safety and Efficacy of Ticagrelor Monotherapy According to Drug-Eluting Stent Type: The TWILIGHT-STENT Study
CONCLUSIONS: As compared with ticagrelor plus aspirin, ticagrelor monotherapy after a short DAPT duration lowered bleeding complications without increasing the ischemic risk, irrespective of DES type. We observed no significant differences among DES-types.PMID:34881696 | DOI:10.4244/EIJ-D-21-00721
Source: EuroIntervention - December 9, 2021 Category: Cardiovascular & Thoracic Surgery Authors: George Dangas Usman Baber Samin K Sharma Gennaro Giustino Samantha Sartori Johny Nicolas Ridhima Goel Shamir R Mehta David J Cohen Dominick J Angiolillo Zhongjie Zhang Anton Camaj Davide Cao Carlo Briguori Dariusz Dudek Javier Escaned Kurt Huber Timothy C Source Type: research
